ReviewCurrent opinion in ophthalmology2019
Advances in dry eye disease treatment.
Review in Current opinion in ophthalmology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05169931 (Clinical Efficacy of Amniotic Membrane Extract Eye Drops in Dry Eye Treatment), which is not on this map. Cited by 122 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Clinical Efficacy of Amniotic Membrane Extract Eye Drops in Dry Eye Treatment
Who cites it
122 citing papers in PubMed, 4 syntheses or guidelines pooled it.
- The Efficacy and Safety of Recombinant Human Nerve Growth Factor (rhNGF) in Patients With Dry Eye Disease: A Systematic Review and Meta-analysis.International ophthalmology · 2026Pooled it
- Bridging the gap in managing dry eye disease: a consensus report by the Taiwan society of cataract and refractive surgeons.BMC ophthalmology · 2024Guideline
- Autologous serum eye drops for patients with dry eye disease: a systematic review and meta-analysis of randomized controlled trials.Frontiers in medicine · 2024Pooled it
- Pooled it
- Prospective pilot randomized controlled study of mini-scleral lenses versus rigid gas permeable lenses in irregular cornea with dry eye.Scientific reports · 2026Trial
- Clinical Efficacy and Safety of Preservative Free Cyclosporine in Dry Eye Disease.Clinical ophthalmology (Auckland, N.Z.) · 2025Trial
- Comparison of therapeutic effects of 0.05% Cyclosporine A versus 0.1% Fluorometholone in Chinese patients with mild dry eye unresponsive to artificial tears: a randomized control study.BMC ophthalmology · 2024Trial
- Recombinant human nerve growth factor (cenegermin) for moderate-to-severe dry eye: phase II, randomized, vehicle-controlled, dose-ranging trial.BMC ophthalmology · 2024Trial
- Efficacy and safety of platelet-rich plasma and autologous-serum eye drops for dry eye in primary Sjögren's syndrome: a randomized trial.Scientific reports · 2023Trial
- Efficacy and Safety of the Melanocortin Pan-Agonist PL9643 in a Phase 2 Study of Patients with Dry Eye Disease.Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics · 2023Trial
- A Randomised Phase I Study to Assess the Safety, Tolerability and Pharmacokinetics of Palovarotene Ophthalmic Solution.Drugs in R&D · 2023Trial
- Performance of a Translucent Activator for LipiFlow Vectored Thermal Pulse (VTP) Treatment of Meibomian Gland Dysfunction.Clinical ophthalmology (Auckland, N.Z.) · 2022Trial
- Evaluating the efficacy of Quantum Molecular Resonance (QMR) electrotherapy in mixed-type dry eye patients.Journal of optometryTrial
- Exosome-based therapies for corneal disorders: current status and future perspectives.MedScience · 2026Review
- The relationship between correction modality and clinical signs and symptoms of dry eye and meibomian gland dysfunction in keratoconic patients.Ophthalmic & physiological optics : the journal of the British College of Ophthalmic Opticians (Optometrists) · 2026Article
- A liposomal formulation of cyclosporine a shows promising results in treating symptoms of moderate to severe dry eye disease in dogs.Drug delivery and translational research · 2026Article
- Dry Eye Disease: From Mechanisms to Management and Future Directions.Journal of clinical medicine · 2026Review
- Corneal epithelial thickness profiles in dry eye patients with or without primary Sjögren's syndrome.BMC ophthalmology · 2026Article
- Mucoadhesive micelles for ophthalmic drug delivery.Journal of biomaterials applications · 2026Article
- Serum Eye Drops: Implementation, Upscaling, and Patient-Centered Care - Insights from a Blood Bank in Western Austria.Transfusion medicine and hemotherapy : offizielles Organ der Deutschen Gesellschaft fur Transfusionsmedizin und Immunhamatologie · 2026Review
62 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
purpose of reviewThe prevalence and burden of dry eye disease continues to grow at a rapid pace, creating an increased need for new therapies. In a sector once limited to only a handful of treatments, clinicians now have multiple options available for patients who fail traditional therapies. This review summarizes the various treatment options available to clinicians treating complex dry eye disease patients. RECENT
findingsAs we better understand the multifactorial mechanisms leading to dry eye disease, treatments increasingly focus on the amelioration of the underlying deficiencies and inflammation, rather than on transient symptomatic relief alone. Most topical medications seek to replace deficient growth factors and/or decrease inflammation on the ocular surface. The majority of new devices and procedures seek to treat meibomian gland dysfunction, with one new device stimulating tear production through utilizing the nasolacrimal reflex pathway. SUMMARY: Clinicians have more options at their disposal in the treatment of dry eye disease than ever before, including topical medications and devices.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.